Eli Lilly Cleared By Jury In Cymbalta Withdrawal Suit

Law360, Washington (September 1, 2015, 4:16 PM EDT) -- A Virginia federal jury cleared drugmaker Eli Lilly & Co. on Tuesday of allegations it had negligently downplayed the risks of Cymbalta withdrawal in its labeling, shooting down the last claims of a trimmed-down suit from two women who claimed they suffered severe withdrawal symptoms.

Plaintiffs claimed Eli Lilly negligently failed to warn their prescribing doctors by understating the withdrawal risks of Cymbalta, which included depression, migraines, pain, fatigue and sensations of electric shocks. (Credit: AP) The jury came back after less than three hours of deliberations Tuesday afternoon to find in Eli Lilly’s favor on allegations that it had negligently...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS